Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary hepatic tumor and the fifth most common cancer worldwide. The incidence continues to rise worldwide due to its association with hepatitis B and C viral infections. Cirrhosis is present concurrently with HCC in approximately 90% of the identified cases [1, 2]. Furthermore, the incidence of HCC increases with the severity of cirrhosis. Follow-up studies have identified HCC as one of the most common causes of death in the cirrhotic patient [3, 4]. The management of HCC, therefore, is based both on the stage of the malignancy and on the underlying functional status of the liver. Local tumor ablative techniques remain a reasonable treatment consideration for patients with disease confined to the liver who are not candidates for resection or transplantation.
| Original language | English (US) |
|---|---|
| Title of host publication | Hepatocellular Carcinoma |
| Subtitle of host publication | Targeted Therapy and Multidisciplinary Care |
| Publisher | Springer New York |
| Pages | 261-273 |
| Number of pages | 13 |
| ISBN (Print) | 9781603275217 |
| DOIs | |
| State | Published - 2011 |
Keywords
- HCC treatment strategy
- Open RFA laparoscopic RFA
- RFA outcomes HCC
- Radiofrequency ablation
ASJC Scopus subject areas
- General Medicine
Divisions
- Surgical Oncology
Fingerprint
Dive into the research topics of 'Radiofrequency ablation for hepatocellular carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS